Table 1.
Baseline Patient and Treatment Characteristics
| Total (n = 108) | |
|---|---|
| Age, mean (range) | 64 (32–90) |
| ECOG performance status, n (%) | |
| 0 | 0 (0) |
| 1 | 23 (21) |
| 2 | 36 (33) |
| 3 | 33 (31) |
| 4 | 16 (15) |
| Histology | |
| Adenocarcinoma | 24 (22) |
| Squamous cell carcinoma | 19 (18) |
| NSCLC NOS | 31 (29) |
| Small cell carcinoma | 13 (12) |
| Metastasis/other | 21 (19) |
| Disease status | |
| New diagnosis | 61 (56) |
| Recurrence of prior cancer | 17 (16) |
| Progression of known disease | 30 (28) |
| Extent of obstruction | |
| Lobar | 88 (81) |
| Entire lung | 20 (19) |
| Maximal tumor size, median (range), cm | 6.5 (2.5–16) |
| <6 cm | 35 (32%) |
| ≥6 cm | 73 (68%) |
| Clinical setting at consultation, n (%) | |
| Outpatient | 39 (36) |
| Inpatient, floor | 62 (57) |
| Inpatient, intensive care | 7 (6) |
| Intubated due to obstruction, n (%) | 7 (6) |
| Lung-directed intervention | 14 (13) |
| Systemic therapy | |
| Before RT | 40 (37) |
| After RT | 27 (25) |
| Any | 51 (47) |
| Duration of pre-RT obstruction, median (IQR) | 17.5 (8–41) |
| ≤30 days | 70 (65) |
| >30 days | 38 (35) |
| Prescription dose (Gy), median (IQR) | 30 (8–30) |
| 30 Gy/10 Fx | 59 (55) |
| 8 Gy/1 Fx | 28 (26) |
| 20 Gy/5 Fx | 11 (10) |
| 16 Gy/2 Fx | 7 (7) |
| 17 Gy/2 Fx | 2 (2) |
| 8.5 Gy/1 Fx | 1 (1) |
ECOG, Eastern Cooperative Oncology Group performance status; NOS, not otherwise specified; NSCLC, nonsmall cell lung cancer; RT, radiotherapy; SCLC, small cell lung cancer.